微卡联合化学治疗初治涂阳肺结核临床观察  

Clinical observation of Mycobacterium vaccae vaccine combined with chemotherapy in treatment of primary smear-positive pulmonary tuberculosis

作　　者：林元敏[1] 钟小林[1] 

机构地区：[1]隆昌县疾病预防控制中心,四川隆昌642150

出　　处：《现代医药卫生》2013年第1期29-30,共2页Journal of Modern Medicine & Health

摘　　要：目的评价微卡治疗初治涂阳肺结核的临床疗效。方法 166例初治涂阳肺结核患者,随机分为治疗组(A组)和对照组(B组)各83例,均采用2H3R3Z3E3/4H3R3方案治疗,A组加用微卡治疗。观察治疗后痰菌阴转、肺部病灶吸收及空洞闭合情况。结果治疗1～2个月痰菌阴转率A组显著高于B组(P<0.05),治疗3～6个月痰菌阴转率A组与B组比较,差异无统计学意义(P>0.05);疗程结束时,胸部病灶显著吸收率:A、B两组分别为88.0%和73.5%;空洞闭合率:A、B两组分别为85.7%和59.4%,两组比较,差异有统计学意义(P<0.05)。结论微卡联合化学治疗初治涂阳肺结核能加快痰菌阴转,促进肺部病灶吸收及空洞闭合,其不良反应小,使用安全,费用低,值得临床推广使用。Objective To evaluation the clinical efficacy of Mycobacterium（M.） vaccae vaccine in the treatment of primary smear-positive pulmonary tuberculosis.Methods 166 patients with primary smear-positive pulmonary tuberculosis were randomly divided into the treatment group（A） and the control group（group B）,83 cases in each group.Both groups were treated with 2H3R3Z3E3/4H3R3 regimen,but the group A was added with M.vaccae vaccine.Sputum bacterial negative conversion,pulmonary lesions absorption and void closure were observed after treatment.Results After 1-2 months treatment,the sputum negative conversion rate in the group A was significantly higher than that in the group B（P0.05）,while after 2-6 months treatment,the sputum negative conversion rate in both groups showed no significant difference（P0.05）;at the end of the treatment,the significant absorption rates of chest lesions in the group A and B were 88% and 73.5% respectively;the void closure rates were 85.7% and 59.4% respectively,difference showing statistical significance（P0.05）.Conclusion M.vaccae vaccine combined with chemotherapy in the treatment of primary smear-positive pulmonary tuberculosis can accelerate the sputum negative conversion,promote pulmonary lesions absorption and void closure,with the mild adverse reactions,safe use and low costs,which is worthy of clinical promotion and application.

关 键 词：结核 肺 治疗 细菌菌苗 治疗应用 卡介苗 治疗应用 药物疗法 联合 微卡 临床观察 

分 类 号：R521.05[医药卫生—内科学]